Top Markets
Coin of the day
Edesa Biotech, Inc. Edesa Biotech, Inc.

Edesa Biotech, Inc.

EDSA
Clasificación en acciones #25934
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Precio por acción
$4.77
Capitalización bursátil
$45.94M
Cambio (1 día)
-17.07%
Cambio (1 año)
102.06%
País
CA
Comercio Edesa Biotech, Inc. (EDSA)

Categoría

Ganancias de Edesa Biotech, Inc. (EDSA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Edesa Biotech, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Edesa Biotech, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US